{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:22:04Z","timestamp":1700785324390},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der systemische Lupus erythematodes (SLE) ist eine Autoimmunerkrankung mit variabler klinischer Pr\u00e4sentation und Organbeteiligung. Eine fr\u00fchzeitige Diagnose sowie das z\u00fcgige Erreichen einer niedrigen Krankheitsaktivit\u00e4t oder Remission reduzieren Organsch\u00e4den und verbessern die Prognose. Die Behandlungsans\u00e4tze lassen sich unterteilen in sogenannte Basisma\u00dfnahmen und die immunsuppressiven Therapien. Die medikament\u00f6sen Therapieoptionen wurden in den letzten Jahren grundlegend erweitert, dabei sind neue Wirkstoffklassen f\u00fcr die Therapie des SLE hinzugekommen. Dies schlie\u00dft Biologikatherapien und zugelassene Therapieoptionen f\u00fcr die Behandlung der Lupusnephritis ein. Aufgrund verbesserter Behandlungsm\u00f6glichkeiten kann unter Einsparung von Glukokortikoiden h\u00e4ufig eine gute Krankheitskontrolle erreicht werden, dabei kommen zunehmend Kombinationstherapien zum Einsatz. Von gro\u00dfer Wichtigkeit ist der konsequente Einsatz der Basisma\u00dfnahmen, hierzu z\u00e4hlen der Einsatz von Hydroxychloroquin, die Optimierung der kardiovaskul\u00e4ren Risikofaktoren, ein Schutz vor ultravioletter Strahlung, knochenprotektive Ma\u00dfnahmen und die Durchf\u00fchrung der Schutzimpfungen. In der Behandlung der Lupusnephritis spielen konservative Therapiema\u00dfnahmen zur Nephroprotektion eine entscheidende Rolle f\u00fcr die renale Prognose. Hinsichtlich einer Verbesserung der Lebensqualit\u00e4t haben auch nichtpharmakologische Therapieoptionen wie die Bewegungstherapie eine gro\u00dfe Bedeutung.<\/jats:p>","DOI":"10.1007\/s00108-023-01624-9","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T17:01:45Z","timestamp":1699376505000},"page":"1135-1142","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Was ist gesichert in der Therapie des systemischen Lupus erythematodes?","What is proven in the treatment of systemic lupus erythematosus?"],"prefix":"10.1007","volume":"64","author":[{"given":"Vega","family":"G\u00f6decke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"issue":"4","key":"1624_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"GJ Pons-Estel","year":"2010","unstructured":"Pons-Estel\u00a0GJ, Alarc\u00f3n\u00a0GS, Scofield\u00a0L, Reinlib\u00a0L, Cooper\u00a0GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257\u2013268","journal-title":"Semin Arthritis Rheum"},{"key":"1624_CR2","doi-asserted-by":"publisher","first-page":"kead519","DOI":"10.1093\/rheumatology\/kead519","volume":"28","author":"SR Moe","year":"2023","unstructured":"Moe\u00a0SR, Haukeland\u00a0H, Brunborg\u00a0C, Botea\u00a0A, Damjanic\u00a0N, Wivestad\u00a0G\u00c5, \u00d8vre\u00e5s\u00a0H, B\u00f8e\u00a0T, Orre\u00a0A, Garen\u00a0T, Lilleby\u00a0V, Provan\u00a0SA, Molberg \u00d8, Lerang\u00a0K (2023) Persisting mortality gap in systemic lupus erythematosus; a\u00a0population-based study on juvenile- and adult-onset SLE in Norway 1999\u20132022. Rheumatology 28:kead519 (Sep)","journal-title":"Rheumatology"},{"issue":"1","key":"1624_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders\u00a0HJ, Saxena\u00a0R, Zhao\u00a0MH, Parodis\u00a0I, Salmon\u00a0JE, Mohan\u00a0C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1624_CR4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer\u00a0M, Costenbader\u00a0K, Daikh\u00a0D, Brinks\u00a0R, Mosca\u00a0M, Ramsey-Goldman\u00a0R, Smolen\u00a0JS, Wofsy\u00a0D, Boumpas\u00a0DT, Kamen\u00a0DL, Jayne\u00a0D, Cervera\u00a0R, Costedoat-Chalumeau\u00a0N, Diamond\u00a0B, Gladman\u00a0DD, Hahn\u00a0B, Hiepe\u00a0F, Jacobsen\u00a0S, Khanna\u00a0D, Lerstr\u00f8m\u00a0K, Massarotti\u00a0E, McCune\u00a0J, Ruiz-Irastorza\u00a0G, Sanchez-Guerrero\u00a0J, Schneider\u00a0M, Urowitz\u00a0M, Bertsias\u00a0G, Hoyer\u00a0BF, Leuchten\u00a0N, Tani\u00a0C, Tedeschi\u00a0SK, Touma\u00a0Z, Schmajuk\u00a0G, Anic\u00a0B, Assan\u00a0F, Chan\u00a0TM, Clarke\u00a0AE, Crow\u00a0MK, Czirj\u00e1k\u00a0L, Doria\u00a0A, Graninger\u00a0W, Halda-Kiss\u00a0B, Hasni\u00a0S, Izmirly\u00a0PM, Jung\u00a0M, Kum\u00e1novics\u00a0G, Mariette\u00a0X, Padjen\u00a0I, Pego-Reigosa\u00a0JM, Romero-Diaz\u00a0J, R\u00faa-Figueroa Fern\u00e1ndez \u00cd, Seror\u00a0R, Stummvoll\u00a0GH, Tanaka\u00a0Y, Tektonidou\u00a0MG, Vasconcelos\u00a0C, Vital\u00a0EM, Wallace\u00a0DJ, Yavuz\u00a0S, Meroni\u00a0PL, Fritzler\u00a0MJ, Naden\u00a0R, D\u00f6rner\u00a0T, Johnson\u00a0SR (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151\u20131159","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1624_CR5","first-page":"288","volume":"29","author":"DD Gladman","year":"2000","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB (2000) Systemic lupus erythematosus disease activity index 2000. J\u00a0Rheumatol 29(2):288\u2013291","journal-title":"J Rheumatol"},{"issue":"12","key":"1624_CR6","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1002\/art.23130","volume":"56","author":"CS Yee","year":"2004","unstructured":"Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D\u2019Cruz D, Khamashta MA, Maddison P, Gordon C (2004) British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 56(12):4113\u20134119. https:\/\/doi.org\/10.1002\/art.23130","journal-title":"Arthritis Rheum."},{"issue":"9","key":"1624_CR7","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn\u00a0K, Lau\u00a0CS, Navarra\u00a0SV, Louthrenoo\u00a0W, Lateef\u00a0A, Hamijoyo\u00a0L, Wahono\u00a0CS, Chen\u00a0SL, Jin\u00a0O, Morton\u00a0S, Hoi\u00a0A, Huq\u00a0M, Nikpour\u00a0M, Morand\u00a0EF (2016) Asia-pacific lupus collaboration. Definition and initial validation of a\u00a0lupus low disease activity state (LLDAS). Ann Rheum Dis 75(9):1615\u20131621","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1624_CR8","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven\u00a0RF, Bertsias\u00a0G, Doria\u00a0A, Isenberg\u00a0D, Morand\u00a0E, Petri\u00a0MA, Pons-Estel\u00a0BA, Rahman\u00a0A, Ugarte-Gil\u00a0MF, Voskuyl\u00a0A, Arnaud\u00a0L, Bruce\u00a0IN, Cervera\u00a0R, Costedoat-Chalumeau\u00a0N, Gordon\u00a0C, Houssiau\u00a0FA, Mosca\u00a0M, Schneider\u00a0M, Ward\u00a0MM, Alarcon\u00a0G, Aringer\u00a0M, Askenase\u00a0A, Bae\u00a0SC, Bootsma\u00a0H, Boumpas\u00a0DT, Brunner\u00a0H, Clarke\u00a0AE, Coney\u00a0C, Czirj\u00e1k\u00a0L, D\u00f6rner\u00a0T, Faria\u00a0R, Fischer\u00a0R, Fritsch-Stork\u00a0R, Inanc\u00a0M, Jacobsen\u00a0S, Jayne\u00a0D, Kuhn\u00a0A, van Leeuw\u00a0B, Limper\u00a0M, Mariette\u00a0X, Navarra\u00a0S, Nikpour\u00a0M, Olesinska\u00a0MH, Pons-Estel\u00a0G, Romero-Diaz\u00a0J, Rubio\u00a0B, Schoenfeld\u00a0Y, Bonf\u00e1\u00a0E, Smolen\u00a0J, Teng\u00a0YKO, Tincani\u00a0A, Tsang-A-Sjoe\u00a0M, Vasconcelos\u00a0C, Voss\u00a0A, Werth\u00a0VP, Zakharhova\u00a0E, Aranow\u00a0C (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8(1):e538","journal-title":"Lupus Sci Med"},{"key":"1624_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Andersen\u00a0J, Aringer\u00a0M, Arnaud\u00a0L, Bae\u00a0SC, Boletis\u00a0J, Bruce\u00a0IN, Cervera\u00a0R, Doria\u00a0A, D\u00f6rner\u00a0T, Furie\u00a0RA, Gladman\u00a0DD, Houssiau\u00a0FA, In\u00eas\u00a0LS, Jayne\u00a0D, Kouloumas\u00a0M, Kov\u00e1cs\u00a0L, Mok\u00a0CC, Morand\u00a0EF, Moroni\u00a0G, Mosca\u00a0M, Mucke\u00a0J, Mukhtyar\u00a0CB, Nagy\u00a0G, Navarra\u00a0S, Parodis\u00a0I, Pego-Reigosa\u00a0JM, Petri\u00a0M, Pons-Estel\u00a0BA, Schneider\u00a0M, Smolen\u00a0JS, Svenungsson\u00a0E, Tanaka\u00a0Y, Tektonidou\u00a0MG, Teng\u00a0YO, Tincani\u00a0A, Vital\u00a0EM, van Vollenhoven\u00a0RF, Wincup\u00a0C, Bertsias\u00a0G, Boumpas\u00a0DT (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1624_CR10","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00108-016-0135-6","volume":"57","author":"M Aringer","year":"2016","unstructured":"Aringer\u00a0M, Schneider\u00a0M (2016) Management des systemischen Lupus erythematodes [Management of systemic lupus erythematosus]. Internist 57(11):1052\u20131059","journal-title":"Internist"},{"key":"1624_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224416","author":"I Parodis","year":"2023","unstructured":"Parodis\u00a0I, Girard-Guyonvarc\u2019h\u00a0C, Arnaud\u00a0L, Distler\u00a0O, Domj\u00e1n\u00a0A, Van den Ende\u00a0CHM, Fligelstone\u00a0K, Kocher\u00a0A, Larosa\u00a0M, Lau\u00a0M, Mitropoulos\u00a0A, Ndosi\u00a0M, Poole\u00a0JL, Redmond\u00a0A, Ritschl\u00a0V, Alexanderson\u00a0H, Sj\u00f6berg\u00a0Y, von Perner\u00a0G, Uhlig\u00a0T, Varju\u00a0C, Vriezekolk\u00a0JE, Welin\u00a0E, Westhovens\u00a0R, Stamm\u00a0TA, Bostr\u00f6m\u00a0C (2023) EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-224416","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1624_CR12","first-page":"298","volume":"1","author":"H Liang","year":"2014","unstructured":"Liang\u00a0H, Tian\u00a0X, Cao\u00a0LY, Chen\u00a0YY, Wang\u00a0CM (2014) Effect of psychological intervention on health-related quality of life in people with systemic lupus erythematosus: a\u00a0systematic review. Int J Nurs Sci 1(3):298\u2013305","journal-title":"Int J Nurs Sci"},{"issue":"1","key":"1624_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s42358-019-0074-8","volume":"59","author":"TC da Hora","year":"2019","unstructured":"da Hora\u00a0TC, Lima\u00a0K, Maciel\u00a0RRBT (2019) The effect of therapies on the quality of life of patients with systemic lupus erythematosus: a\u00a0meta-analysis of randomized trials. Adv Rheumatol 59(1):34","journal-title":"Adv Rheumatol"},{"issue":"11","key":"1624_CR14","doi-asserted-by":"publisher","first-page":"102393","DOI":"10.1016\/j.autrev.2019.102393","volume":"18","author":"D Parisis","year":"2019","unstructured":"Parisis\u00a0D, Bernier\u00a0C, Chasset\u00a0F, Arnaud\u00a0L (2019) Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A\u00a0systematic review and meta-analysis. Autoimmun Rev 18(11):102393","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1624_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"Canadian Hydroxychloroquine Study Group (1991) A\u00a0randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N\u00a0Engl J Med 324(3):150\u2013154","journal-title":"N Engl J Med"},{"issue":"1","key":"1624_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza\u00a0G, Ramos-Casals\u00a0M, Brito-Zeron\u00a0P, Khamashta\u00a0MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a\u00a0systematic review. Ann Rheum Dis 69(1):20\u201328","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1624_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/art.25052","volume":"62","author":"EM Ginzler","year":"2010","unstructured":"Ginzler\u00a0EM, Wofsy\u00a0D, Isenberg\u00a0D, Gordon\u00a0C, Lisk\u00a0L, Dooley\u00a0MA, ALMS Group (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a\u00a0multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62(1):211\u2013221","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1624_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros\u00a0J, S\u00e1ez-Comet\u00a0L, P\u00e9rez-Conesa\u00a0M, Vidal\u00a0X, Mitjavila\u00a0F, Castro\u00a0SA, Cuquet Pedragosa\u00a0J, Ortiz-Santamaria\u00a0V, Plana\u00a0MM, Cort\u00e9s-Hern\u00e1ndez\u00a0J (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a\u00a0randomised clinical trial. Ann Rheum Dis 76(9):1575\u20131582","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1624_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00393-013-1213-y","volume":"72","author":"M Aringer","year":"2013","unstructured":"Aringer\u00a0M, Fischer-Betz\u00a0R, Hiepe\u00a0F, Kommission Pharmakotherapie der DGRh Germany Society of Rheumatology (2013) Stellungnahme zum Einsatz von Mycophenolat-Mofetil beim systemischen Lupus erythematodes [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Z\u00a0Rheumatol 72(6):575\u2013580","journal-title":"Z Rheumatol"},{"issue":"9767","key":"1624_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra\u00a0SV, Guzm\u00e1n\u00a0RM, Gallacher\u00a0AE, Hall\u00a0S, Levy\u00a0RA, Jimenez\u00a0RE, Li\u00a0EK, Thomas\u00a0M, Kim\u00a0HY, Le\u00f3n\u00a0MG, Tanasescu\u00a0C, Nasonov\u00a0E, Lan\u00a0JL, Pineda\u00a0L, Zhong\u00a0ZJ, Freimuth\u00a0W, Petri\u00a0MA, BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 377(9767):721\u2013731","journal-title":"Lancet"},{"issue":"12","key":"1624_CR21","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie\u00a0R, Petri\u00a0M, Zamani\u00a0O, Cervera\u00a0R, Wallace\u00a0DJ, Tegzov\u00e1\u00a0D, Sanchez-Guerrero\u00a0J, Schwarting\u00a0A, Merrill\u00a0JT, Chatham\u00a0WW, Stohl\u00a0W, Ginzler\u00a0EM, Hough\u00a0DR, Zhong\u00a0ZJ, Freimuth\u00a0W, van Vollenhoven\u00a0RF, BLISS-76 Study Group (2011) A\u00a0phase\u00a0III, randomized, placebo-controlled study of belimumab, a\u00a0monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u20133930","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1624_CR22","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F, Malvar\u00a0A, Teng\u00a0YKO, Contreras\u00a0G, Amoura\u00a0Z, Yu\u00a0X, Mok\u00a0CC, Santiago\u00a0MB, Saxena\u00a0A, Green\u00a0Y, Ji\u00a0B, Kleoudis\u00a0C, Burriss\u00a0SW, Barnett\u00a0C, Roth\u00a0DA (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N\u00a0Engl J Med 383(12):1117\u20131128","journal-title":"N Engl J Med"},{"issue":"3","key":"1624_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y, Bruce\u00a0IN, Askanase\u00a0AD, Richez\u00a0C, Bae\u00a0SC, Brohawn\u00a0PZ, Pineda\u00a0L, Berglind\u00a0A, Tummala\u00a0R, TULIP\u20112 Trial Investigators (2020) Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N\u00a0Engl J Med 382(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"2","key":"1624_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H (2023) A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 75(2):253\u2013265. https:\/\/doi.org\/10.1002\/art.42392","journal-title":"Arthritis Rheumatol"},{"issue":"10289","key":"1624_CR25","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Teng\u00a0YKO, Ginzler\u00a0EM, Arriens\u00a0C, Caster\u00a0DJ, Romero-Diaz\u00a0J, Gibson\u00a0K, Kaplan\u00a0J, Lisk\u00a0L, Navarra\u00a0S, Parikh\u00a0SV, Randhawa\u00a0S, Solomons\u00a0N, Huizinga\u00a0RB (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase\u00a03\u00a0trial. Lancet 397(10289):2070\u20132080","journal-title":"Lancet"},{"key":"1624_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/art.42657","author":"A Saxena","year":"2023","unstructured":"Saxena\u00a0A, Ginzler\u00a0EM, Gibson\u00a0K, Satirapoj\u00a0B, Santill\u00e1n\u00a0AEZ, Levchenko\u00a0O, Navarra\u00a0S, Atsumi\u00a0T, Yasuda\u00a0S, Chavez-Perez\u00a0NN, Arriens\u00a0C, Parikh\u00a0SV, Caster\u00a0DJ, Birardi\u00a0V, Randhawa\u00a0S, Lisk\u00a0L, Huizinga\u00a0RB, Teng\u00a0YKO (2023) Safety and efficacy of long-term Voclosporin treatment for lupus nephritis in the phase\u00a03 AURORA 2 clinical trial. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42657","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1624_CR27","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1002\/art.20666","volume":"50","author":"FA Houssiau","year":"2004","unstructured":"Houssiau\u00a0FA, Vasconcelos\u00a0C, D\u2019Cruz\u00a0D, Sebastiani\u00a0GD, de Ramon Garrido\u00a0E, Danieli\u00a0MG, Abramovicz\u00a0D, Blockmans\u00a0D, Mathieu\u00a0A, Direskeneli\u00a0H, Galeazzi\u00a0M, G\u00fcl\u00a0A, Levy\u00a0Y, Petera\u00a0P, Popovic\u00a0R, Petrovic\u00a0R, Sinico\u00a0RA, Cattaneo\u00a0R, Font\u00a0J, Depresseux\u00a0G, Cosyns\u00a0JP, Cervera\u00a0R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50(12):3934\u20133940","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1624_CR28","first-page":"1275","volume":"26","author":"JR Carneiro","year":"1999","unstructured":"Carneiro\u00a0JR, Sato\u00a0EI (1999) Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J\u00a0Rheumatol 26(6):1275\u20131279","journal-title":"J Rheumatol"},{"issue":"4","key":"1624_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin\u00a0BH, Furie\u00a0R, Latinis\u00a0K, Looney\u00a0RJ, Fervenza\u00a0FC, Sanchez-Guerrero\u00a0J, Maciuca\u00a0R, Zhang\u00a0D, Garg\u00a0JP, Brunetta\u00a0P, Appel\u00a0G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215\u20131226. https:\/\/doi.org\/10.1002\/art.34359","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1624_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","volume":"5","author":"F Alshaiki","year":"2018","unstructured":"Alshaiki\u00a0F, Obaid\u00a0E, Almuallim\u00a0A, Taha\u00a0R, El-Haddad\u00a0H, Almoallim\u00a0H (2018) Outcomes of rituximab therapy in refractory lupus: a\u00a0meta-analysis. Eur J Rheumatol 5(2):118\u2013126. https:\/\/doi.org\/10.5152\/eurjrheum.2018.17096","journal-title":"Eur J Rheumatol"},{"issue":"10","key":"1624_CR31","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3899\/jrheum.2022-1135","volume":"50","author":"F Crisafulli","year":"2023","unstructured":"Crisafulli\u00a0F, Andreoli\u00a0L, Zucchi\u00a0D, Reggia\u00a0R, Gerardi\u00a0MC, Lini\u00a0D, Tani\u00a0C, Zatti\u00a0S, Franceschini\u00a0F, Mosca\u00a0M, Tincani\u00a0A (2023) Variations of C3 and C4 before and during pregnancy in systemic lupus erythematosus: association with disease flares and obstetric outcomes. J\u00a0Rheumatol 50(10):1296\u20131301","journal-title":"J Rheumatol"},{"issue":"3","key":"1624_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli\u00a0L, Bertsias\u00a0GK, Agmon-Levin\u00a0N, Brown\u00a0S, Cervera\u00a0R, Costedoat-Chalumeau\u00a0N, Doria\u00a0A, Fischer-Betz\u00a0R, Forger\u00a0F, Moraes-Fontes\u00a0MF, Khamashta\u00a0M, King\u00a0J, Lojacono\u00a0A, Marchiori\u00a0F, Meroni\u00a0PL, Mosca\u00a0M, Motta\u00a0M, Ostensen\u00a0M, Pamfil\u00a0C, Raio\u00a0L, Schneider\u00a0M, Svenungsson\u00a0E, Tektonidou\u00a0M, Yavuz\u00a0S, Boumpas\u00a0D, Tincani\u00a0A (2017) EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476\u2013485","journal-title":"Ann Rheum Dis"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01624-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T09:02:36Z","timestamp":1700730156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01624-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01624-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"24 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.\u00a0G\u00f6decke erkl\u00e4rt, Honorare f\u00fcr Vortr\u00e4ge sowie Reisekostenzusch\u00fcsse von AstraZeneca, GSK, Novartis und Otsuka und Beraterhonorare von Novartis erhalten zu haben. T.\u00a0Witte erkl\u00e4rt, Honorare f\u00fcr Vortr\u00e4ge von AstraZeneca und von GSK erhalten zu haben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}